Josh Gottheimer buys and sells multiple stocks in Morgan Stanley account

EditorAhmed Abdulazez Abdulkadir
Published 02/12/2025, 04:55 AM
Josh Gottheimer buys and sells multiple stocks in Morgan Stanley account

New Jersey's 5th congressional district representative, Josh Gottheimer, has been active in the stock market, according to a recent congressional trade report. The report details multiple transactions carried out through a Morgan Stanley (NYSE:MS) - Select UMA Account.

Gottheimer has purchased stocks from several companies, including 3M Company (NYSE:MMM), Abbott Laboratories (NYSE:ABT), Alibaba Group Holding Limited (NYSE:BABA), and Ambev S.A. (NYSE:ABEV). Each of these purchases falls within the $1,001 - $15,000 range.

In addition to these purchases, the congressman also invested in stocks from Berkshire Hathaway Inc . (NYSE:BRKa) (NYSE:BRK.B), Cadre Holdings , Inc. (NYSE:CDRE), Coca-Cola Company (NYSE:KO), and Corning Incorporated (NYSE:GLW). All these investments also fall within the $1,001 - $15,000 range. With a market capitalization of $81.26 billion and a P/E ratio of 19.79, 3M demonstrates solid fundamentals. InvestingPro subscribers have access to over 10 additional exclusive insights and detailed financial metrics for each of these companies.

The report also reveals that Gottheimer has sold off part of his stakes in several companies. These include Alphabet (NASDAQ:GOOGL) Inc. (NASDAQ:GOOG), Arista Networks , Inc. (NYSE:ANET), Broadcom Inc. (NASDAQ:AVGO), and Eaton Corporation, PLC (NYSE:ETN). Each of these partial sales is also valued between $1,001 and $15,000.

However, one transaction stood out from the rest. Gottheimer sold off his full stake in Merck (NSE:PROR) & Company, Inc. (NYSE:MRK), valued between $15,001 and $50,000.

The transactions were all conducted in January 2025, with the notification date being February 6, 2025.

The report provides a glimpse into the investment strategies of one of the members of Congress. However, it's essential to remember that these transactions do not necessarily reflect the congressman's views on the companies involved or their future performance in the stock market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.